All Releases
 |
Amicus Therapeutics to Present at UBS Global Healthcare Conference
May 14, 2013
|
9.2 KB |
| |
CRANBURY, N.J., May 14, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 2013 UBS Global Healthcare Conference in New York, NY on Tuesday, May 21, 2013 at 1:30 p.m. ET. A live webcast of the presentation can be accessed thr...
|
|
Amicus Therapeutics Announces First Quarter 2013 Financial Results and Corporate Updates
May 9, 2013
|
35.7 KB |
| |
12-Month Results From Ongoing Phase 3 Fabry Disease Monotherapy Study Anticipated 3Q13
Phase 2b Pompe Co-Administration Study on Track to Begin 3Q13
CRANBURY, N.J., May 9, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announce...
|
|
Amicus Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013
May 2, 2013
|
9.1 KB |
| |
CRANBURY, N.J., May 2, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Thursday, May 9, 2013 at 5:00 p.m. ET to discuss financial results for the first quarter ended March 31, 2013.
The call with be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will...
|
|
Amicus Therapeutics to Present at 12th Annual Needham Healthcare Conference
Apr 24, 2013
|
9.3 KB |
| |
CRANBURY, N.J., April 24, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 12th Annual Needham Healthcare Conference in New York, NY on Tuesday, April 30, 2013 at 5:00 p.m. ET. A live webcast of the presentation can be acce...
|
|
Amicus Therapeutics Announces Full-Year 2012 Financial Results and Corporate Updates
Mar 12, 2013
|
36.2 KB |
| |
CHART Programs Advancing in Lysosomal Storage Diseases
12-Month Results from Ongoing Phase 3 Fabry Disease Monotherapy Study Expected 3Q13
CRANBURY, N.J., March 12, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced finan...
|
|
Amicus Therapeutics to Announce Full-Year 2012 Financial Results on March 12, 2013
Mar 7, 2013
|
9.0 KB |
| |
CRANBURY, N.J., March 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, March 12, 2013 at 5:00 p.m. ET to discuss financial results for the full-year ended December 31, 2012.
The call with be hosted by John F. Crowley, Chairman and Chief Executive Officer. He w...
|
|
Amicus Therapeutics Introduces Proprietary "CHART" Platform Technology
Mar 4, 2013
|
12.2 KB |
| |
CRANBURY, N.J., March 4, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today introduced Chaperone-Advanced Replacement Therapy (CHART™) as the brand name for its technology platform that combines unique pharmacological chaperones with enzyme replacement therapy (ERT) for lysosomal storage diseases.
John F. Crowley, Chair...
|
|
Amicus Therapeutics to Present at Cowen and Company 33rd Annual Health Care Conference
Feb 27, 2013
|
8.5 KB |
| |
CRANBURY, N.J., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview during the Cowen and Company 33rd Annual Health Care Conference in Boston, MA on Monday, March 4, 2013 at 4:50 p.m. ET. A live webcast of the presentation c...
|
|
Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium
Feb 15, 2013
|
63.8 KB |
| |
CRANBURY, N.J. and ORLANDO, Fla., Feb. 15, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced additional 6-month (Stage 1) results from the first ongoing Phase 3 global registration study (Study 011) of investigational oral migalastat HCl monotherapy (150 mg, every-other-day) in males and females with Fabry disease who had ...
|
|
Amicus Therapeutics Advances Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform in Pompe Disease
Feb 14, 2013
|
23.8 KB |
| |
Phase 2 AT2220-ERT Co-Administration and Preclinical AT2220-ERT Co-Formulation Studies Presented at LDN WORLD Symposium
Next-Generation ERT Advancing in Preclinical Studies
Conference Call on February 15, 2013 at 11:30am ET
CRANBURY, N.J., and ORLANDO, Fla., Feb. 14, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:F...
|
|
Amicus Therapeutics Presents Additional Results From Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease at LDN World Symposium
Feb 13, 2013
|
61.9 KB |
| |
CRANBURY, N.J. and ORLANDO, Fla., Feb. 13, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced further results from an open-label Phase 2 drug-drug interaction study (Study 013) to evaluate a single oral dose of migalastat HCl (150 mg or 450 mg) co-administered prior to enzyme replacement therapy (ERT) in males with Fabry di...
|
|
Amicus Therapeutics Announces Posters and Presentations at Lysosomal Disease Network WORLD Symposium
Feb 7, 2013
|
15.7 KB |
| |
CRANBURY, N.J., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that 2 oral presentations and 5 posters related to its investigational pharmacological chaperones will be included at the 9th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 13-15, 2013 in Orlando, FL. The Company wil...
|
|
Amicus Therapeutics to Participate in BIO CEO & Investor Conference and Leerink Swann Global Healthcare Conference
Feb 4, 2013
|
9.2 KB |
| |
CRANBURY, N.J., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in two upcoming conferences in February.
15th Annual BIO CEO & Investor Conference in New York, NY
Mr. Crowley will participate in a panel, "Orphan Drugs: Ma...
|
|
Amicus Therapeutics Provides Full-Year 2013 Financial Guidance and Strategic Outlook
Jan 7, 2013
|
25.5 KB |
| |
6-Month (Stage 1) Results from Ongoing Phase 3 Fabry Disease Monotherapy Study at Lysosomal Storage Disease Network WORLD Symposium (LDN WORLD) in February 2013; 12-Month Results Expected in 2Q13
Pompe, Fabry and Other New Chaperone-Enzyme Replacement Therapy (ERT) Programs Advancing in 2013
FY13 Cash Spend Guidance Range of $52-$58...
|
|
Amicus Therapeutics Announces Positive Results From All Four Cohorts in Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease
Jan 4, 2013
|
67.1 KB |
| |
Strong Proof-of-Concept Data for Chaperone's Ability to Stabilize and Enhance Activity and Uptake of Currently Marketed ERT Products for Pompe Disease
Results to be Presented at LDN WORLD Symposium in February 2013
Initiation of Repeat-Dose Pompe Study Anticipated in 3Q13
CRANBURY, N.J., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Amic...
|
|
Amicus Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference
Jan 2, 2013
|
8.3 KB |
| |
CRANBURY, N.J., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in S...
|
|
Amicus Therapeutics and GlaxoSmithKline Announce Top Line 6-Month Primary Treatment Period Results From First Phase 3 Fabry Monotherapy Study
Dec 19, 2012
|
62.6 KB |
| |
CRANBURY, N.J. and LONDON, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) and GlaxoSmithKline plc (GSK) today announced the 6-month primary treatment period results from the first Phase 3 global registration study (Study 011) of investigational oral migalastat HCl monotherapy in males and females with Fabry disease who had gene...
|
|
Amicus Therapeutics to Present at Lazard Capital Markets' Healthcare Conference
Nov 12, 2012
|
8.3 KB |
| |
CRANBURY, N.J., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that William D. Baird, III, Chief Financial Officer, will present a corporate overview at the Lazard Capital Markets' 9th Annual Healthcare Conference...
|
|
Amicus Therapeutics Announces Additional Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Study for Fabry Disease
Nov 8, 2012
|
57.6 KB |
| |
CRANBURY, N.J., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), today announced additional preliminary results from an open-label Phase 2 drug-drug interaction study (Study 013) to evaluate a single oral dose of migalastat HCl (150 mg or 450 mg) co-administered with enzyme replacement therapy (ERT) in males with Fabry disease. I...
|
|
Amicus Therapeutics Announces Third Quarter 2012 Financial Results & Corporate Updates
Nov 5, 2012
|
37.6 KB |
| |
6-Month Results Expected 4Q12 and 12-Month Results Anticipated 1H13 From Phase 3 Fabry Monotherapy Study 011
Additional Human Proof-of-Concept Demonstrated for Chaperone-Enzyme Replacement Therapy (ERT) Combination Platform
CRANBURY, N.J., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical comp...
|
|
|
